{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:10:43Z","timestamp":1790637043456,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pharmthera.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T01:49:57Z","timestamp":1423705797000},"page":"169-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["HIF targets in bone remodeling and metastatic disease"],"prefix":"10.1016","volume":"150","author":[{"given":"Rachelle W.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernestina","family":"Schipani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amato J.","family":"Giaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.02.002_bb0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1148\/55.4.534","article-title":"Skeletal metastases in carcinoma","volume":"55","author":"Abrams","year":"1950","journal-title":"Radiology"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0015","first-page":"471","article-title":"SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0020","first-page":"1011","article-title":"Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \u201cstandard of care\u201d therapeutic agents for the treatment of breast cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00774-011-0273-9","article-title":"Unraveling the transcriptional regulatory machinery in chondrogenesis","volume":"29","author":"Akiyama","year":"2011","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0030","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1242\/dev.008441","article-title":"Hif1alpha regulation of Sox9 is necessary to maintain differentiation of hypoxic prechondrogenic cells during early chondrogenesis","volume":"134","author":"Amarilio","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm0111-25","article-title":"Lack of HIF-2alpha in limb bud mesenchyme causes a modest and transient delay of endochondral bone development","volume":"17","author":"Araldi","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0050","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.68.1.1","article-title":"CXC chemokines in angiogenesis","volume":"68","author":"Belperio","year":"2000","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2015.02.002_bb9000","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4103\/0973-1482.110385","article-title":"A retrospective study of incidence of bone metastasis in head and neck cancer","volume":"9","author":"Bhandari","year":"2013","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0060","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/382829a0","article-title":"The lymphocyte chemoattractant SDF-1 is a ligand for LESTR\/fusin and blocks HIV-1 entry","volume":"382","author":"Bleul","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0065","first-page":"261","article-title":"Role of transforming growth factor-beta in bone remodeling","author":"Bonewald","year":"1990","journal-title":"Clin Orthop Relat Res."},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jnci\/93.4.309","article-title":"Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis","volume":"93","author":"Bos","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0075","first-page":"1318","article-title":"Bone secondaries in breast cancer: the solitary metastasis","volume":"30","author":"Boxer","year":"1989","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/0008-5472.CAN-10-1708","article-title":"PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis","volume":"71","author":"Catena","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0090","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0006-3495(01)75732-3","article-title":"Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model","volume":"81","author":"Chow","year":"2001","journal-title":"Biophys J"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eururo.2013.07.026","article-title":"Balancing toxicity and efficacy: Learning from trials and treatment using antiresorptive therapy in prostate cancer","volume":"65","author":"Clarke","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0105","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.exphem.2006.04.002","article-title":"Mutual, reciprocal SDF-1\/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD\/SCID chimeric mice","volume":"34","author":"Dar","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0115","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinthera.2012.02.002","article-title":"Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data","volume":"34","author":"Dempster","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0125","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1097\/01.ASN.0000024380.91444.C8","article-title":"The breathing kidney","volume":"13","author":"Fine","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb9005","series-title":"Bone metastases","first-page":"49","article-title":"The anatomy and pathways of skeletal metastases","author":"Galasko","year":"1981"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0135","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eururo.2013.05.015","article-title":"Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappaB ligand inhibitors in patients with advanced prostate cancer","volume":"65","author":"Gartrell","year":"2014","journal-title":"European Urology"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/BF03349262","article-title":"The critical role of SDF-1\/CXCR4 axis in cancer and cancer stem cells metastasis","volume":"31","author":"Gelmini","year":"2008","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0145","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","article-title":"Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature","volume":"38","author":"Gnant","year":"2012","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0155","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0160","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1158\/0008-5472.CAN-04-3833","article-title":"Blockade of the stromal cell-derived factor-1\/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner","volume":"65","author":"Guleng","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0165","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0170","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1158\/0008-5472.CAN-06-2355","article-title":"Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer","volume":"67","author":"Hiraga","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmthera.2015.02.002_bb9010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccr.2006.08.026","article-title":"Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype","volume":"10","author":"Holmquist-Mengelbier","year":"2006","journal-title":"Cancer Cell."},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0175","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL","volume":"417","author":"Hon","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0180","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1073\/pnas.95.14.7987","article-title":"Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway","volume":"95","author":"Huang","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","article-title":"Systemic spread is an early step in breast cancer","volume":"13","author":"Husemann","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.clbc.2011.05.001","article-title":"Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients","volume":"11","author":"Ibrahim","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","article-title":"Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer","volume":"5","author":"Junankar","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0200","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/jcp.21446","article-title":"Hypoxia promotes chondrogenesis in rat mesenchymal stem cells: A role for AKT and hypoxia-inducible factor (HIF)-1alpha","volume":"216","author":"Kanichai","year":"2008","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0205","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature01654","article-title":"The complexities of skeletal biology","volume":"423","author":"Karsenty","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JTO.0000000000000051","article-title":"Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13","volume":"9","author":"Katakami","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0215","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","article-title":"Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma","volume":"48","author":"Keizman","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0220","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/ar2211","article-title":"Hypoxic conditions increase hypoxia-inducible transcription factor 2alpha and enhance chondrogenesis in stem cells from the infrapatellar fat pad of osteoarthritis patients","volume":"9","author":"Khan","year":"2007","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0225","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1016\/j.ejca.2014.08.003","article-title":"Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis","volume":"50","author":"Kim","year":"2014","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0230","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0235","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature01657","article-title":"Developmental regulation of the growth plate","volume":"423","author":"Kronenberg","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature13145","article-title":"Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone","volume":"507","author":"Kusumbe","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/bdrc.20048","article-title":"Transcriptional control of chondrocyte fate and differentiation","volume":"75","author":"Lefebvre","year":"2005","journal-title":"Birth Defects Res Part C"},{"issue":"7","key":"10.1016\/j.pharmthera.2015.02.002_bb9020","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/1097-0347(200010)22:7<680::AID-HED7>3.0.CO;2-J","article-title":"Distant metastases in head and neck cancer patients who achieved loco-regional control","volume":"22","author":"Le\u00f3n","year":"2000","journal-title":"Head Neck"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0250","doi-asserted-by":"crossref","first-page":"33533","DOI":"10.1074\/jbc.M112.392332","article-title":"Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis","volume":"287","author":"Liang","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0260","first-page":"575","article-title":"Hypoxia promotes the proliferation of cervical carcinoma cells through stimulating the secretion of IL-8","volume":"7","author":"Liu","year":"2014","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"6","key":"10.1016\/j.pharmthera.2015.02.002_bb9015","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1074\/jbc.M109.068577","article-title":"Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha.J","volume":"285","author":"Luo","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0265","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jbmr.1487","article-title":"VEGF-independent cell-autonomous functions of HIF-1alpha regulating oxygen consumption in fetal cartilage are critical for chondrocyte survival","volume":"27","author":"Maes","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0270","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrrheum.2012.36","article-title":"Hypoxia-driven pathways in bone development, regeneration and disease","volume":"8","author":"Maes","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0275","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ydbio.2014.06.013","article-title":"Loss of VHL in mesenchymal progenitors of the limb bud alters multiple steps of endochondral bone development","volume":"393","author":"Mangiavini","year":"2014","journal-title":"Dev Biol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0280","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.4161\/cc.9.18.12931","article-title":"Hypoxia induces PTHrP gene transcription in human cancer cells through the HIF-2alpha","volume":"9","author":"Manisterski","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0285","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/bdd.770","article-title":"Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women","volume":"32","author":"Marathe","year":"2011","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0295","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0300","doi-asserted-by":"crossref","first-page":"C355","DOI":"10.1152\/ajpcell.00398.2009","article-title":"Differential effects of hypoxia on osteochondrogenic potential of human adipose-derived stem cells","volume":"298","author":"Merceron","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0305","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clgc.2013.04.001","article-title":"Long-term response to sunitinib therapy for metastatic renal cell carcinoma","volume":"11","author":"Molina","year":"2013","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0310","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0315","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"Muller","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0320","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0325","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1442-2042.2012.03204.x","article-title":"Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients","volume":"20","author":"Neri","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0335","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/382833a0","article-title":"The CXC chemokine SDF-1 is the ligand for LESTR\/fusin and prevents infection by T-cell-line-adapted HIV-1","volume":"382","author":"Oberlin","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0330","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0340","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000346484","article-title":"Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma","volume":"58","author":"Park","year":"2012","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0345","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.0701152104","article-title":"Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia","volume":"104","author":"Parmar","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0350","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2214\/ajr.155.1.2112830","article-title":"Metastases from malignant melanoma to the axial skeleton: A CT study of frequency and appearance","volume":"155","author":"Patten","year":"1990","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0355","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1242\/dev.01138","article-title":"Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development","volume":"131","author":"Pfander","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0360","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2125.2004.02224.x","article-title":"A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis","volume":"58","author":"Pillai","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0365","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: A national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0370","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bbrc.2004.11.068","article-title":"Molecular mechanisms of endochondral bone development","volume":"328","author":"Provot","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0375","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1196\/annals.1402.076","article-title":"Fetal growth plate: A developmental model of cellular adaptation to hypoxia","volume":"1117","author":"Provot","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0380","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"182","author":"Purcell","year":"2005","journal-title":"Med J Aust"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0385","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature13146","article-title":"Endothelial Notch activity promotes angiogenesis and osteogenesis in bone","volume":"507","author":"Ramasamy","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0390","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11914-011-0047-2","article-title":"A central role for hypoxic signaling in cartilage, bone, and hematopoiesis","volume":"9","author":"Rankin","year":"2011","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0400","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2012.01.051","article-title":"The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO","volume":"149","author":"Rankin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0405","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.1324290111","article-title":"Up-regulation of glycolytic metabolism is required for HIF1alpha-driven bone formation","volume":"111","author":"Regan","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0410","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02408534","article-title":"Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats","volume":"32","author":"Reitsma","year":"1980","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0415","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihimaki","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0420","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bone.2005.04.040","article-title":"Hypoxia induces chondrocyte-specific gene expression in mesenchymal cells in association with transcriptional activation of Sox9","volume":"37","author":"Robins","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0430","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0425","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","article-title":"Bone safety of long-term bisphosphonate treatment","volume":"20","author":"Rodan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0435","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nm.2146","article-title":"Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development","volume":"16","author":"Saito","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0440","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0002-9440(10)65365-5","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha","volume":"154","author":"Salcedo","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0445","doi-asserted-by":"crossref","first-page":"40007","DOI":"10.1074\/jbc.M403715200","article-title":"Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts","volume":"279","author":"Salim","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0450","doi-asserted-by":"crossref","first-page":"e83026","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0455","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0460","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2015.02.002_bb9025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1677\/jme.0.0330227","article-title":"Alternative splicing of parathyroid hormone-related protein mRNA: expression and stability","volume":"33","author":"Sellers","year":"2004","journal-title":"J Mol Endocrinol."},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0465","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1101\/gad.934301","article-title":"Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival","volume":"15","author":"Schipani","year":"2001","journal-title":"Genes and Development"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0470","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/bcr3087","article-title":"Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer","volume":"14","author":"Schwab","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0475","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2353\/ajpath.2010.090310","article-title":"VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis","volume":"176","author":"Seagroves","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0480","first-page":"236","article-title":"Characterization of solid tumor microvasculature: A three-dimensional analysis using the polymer casting technique","volume":"58","author":"Shah-Yukich","year":"1988","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0485","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1148\/112.2.361","article-title":"18F bone scanning: Review of indications and results of 1500 scans","volume":"112","author":"Shirazi","year":"1974","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2015.02.002_bb0490","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0495","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0500","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0505","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01874","article-title":"Chemokine receptor CXCR4 downregulated by von Hippel\u2013Lindau tumour suppressor pVHL","volume":"425","author":"Staller","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0510","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bone.2010.07.015","article-title":"Advances in the biology of bone metastasis: How the skeleton affects tumor behavior","volume":"48","author":"Sterling","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0515","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0520","doi-asserted-by":"crossref","first-page":"27348","DOI":"10.1074\/jbc.270.45.27348","article-title":"The functional role of the ELR motif in CXC chemokine-mediated angiogenesis","volume":"270","author":"Strieter","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0525","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2010.227","article-title":"Bone metastasis: Mechanisms and therapeutic opportunities","volume":"7","author":"Suva","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0530","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.24710","article-title":"Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha\/VEGF signaling pathways in human breast cancer cells","volume":"126","author":"Tang","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0535","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semradonc.2011.12.006","article-title":"Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy","volume":"22","author":"Toustrup","year":"2012","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0540","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00520-010-1061-0","article-title":"RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): Non bis in idem?","volume":"19","author":"Van den Wyngaert","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0545","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2001-14779","article-title":"Hypoxia in cervical cancer: Pathogenesis, characterization, and biological\/clinical consequences","volume":"123","author":"Vaupel","year":"2001","journal-title":"Zentralbl Gyn\u00e4kol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0550","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0555","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/ajmg.a.34325","article-title":"Whole-exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA)","volume":"155A","author":"Vissers","year":"2011","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0560","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI31581","article-title":"The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development","volume":"117","author":"Wang","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0565","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2009-07-233437","article-title":"Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: Serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches","volume":"116","author":"Winkler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0575","first-page":"5679","article-title":"Molecular signature associated with bone marrow micrometastasis in human breast cancer","volume":"63","author":"Woelfle","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0580","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/nm.3668","article-title":"PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0585","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-007-9742-1","article-title":"Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer","volume":"110","author":"Yamamoto","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0590","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1242\/dev.01053","article-title":"VEGFA is necessary for chondrocyte survival during bone development","volume":"131","author":"Zelzer","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0595","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0070-2153(04)65006-X","article-title":"Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair","volume":"65","author":"Zelzer","year":"2005","journal-title":"Curr Top Dev Biol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0600","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","article-title":"Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases","volume":"136","author":"Zolnierek","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.02.002_bb0605","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.ejca.2008.07.011","article-title":"Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone","volume":"44","author":"Zwolak","year":"2008","journal-title":"Eur J Cancer"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T09:38:28Z","timestamp":1691228308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":124,"alternative-id":["S0163725815000467"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.02.002","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIF targets in bone remodeling and metastatic disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}